Trial Profile
A double-blind, double dummy, randomized parallel design trial to evaluate the effects of 12 weeks of treatment with 300 mg aliskiren compared to 5 mg amlodipine on insulin resistance and coronary endothelial function in hypertensive patients with metabolic syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine
- Indications Glucose intolerance; Hypertension; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 27 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.